ARVN Stock Overview
A clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Arvinas, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.48 |
| 52 Week High | US$53.08 |
| 52 Week Low | US$17.37 |
| Beta | 1.83 |
| 1 Month Change | -28.54% |
| 3 Month Change | -23.70% |
| 1 Year Change | -53.38% |
| 3 Year Change | -77.26% |
| 5 Year Change | -55.79% |
| Change since IPO | 15.14% |
Recent News & Updates
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Nov 28
Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Oct 16Recent updates
Investors Still Waiting For A Pull Back In Arvinas, Inc. (NASDAQ:ARVN)
Nov 28Arvinas: Major Catalyst Ahead, But Its History Gives Me Pause
Oct 16Arvinas, Inc. (NASDAQ:ARVN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aug 02Arvinas: Hugely Important Data Catalyst Upcoming - Success May Prove Elusive
Jul 12Here's Why We're Watching Arvinas' (NASDAQ:ARVN) Cash Burn Situation
Jun 27Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Aug 13There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price
May 05Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Feb 24Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Sep 09Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Aug 19Shareholder Returns
| ARVN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.2% | -1.6% | -2.4% |
| 1Y | -53.4% | 7.8% | 23.3% |
Return vs Industry: ARVN underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: ARVN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| ARVN volatility | |
|---|---|
| ARVN Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ARVN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ARVN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 445 | John Houston | www.arvinas.com |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial.
Arvinas, Inc. Fundamentals Summary
| ARVN fundamental statistics | |
|---|---|
| Market cap | US$1.27b |
| Earnings (TTM) | -US$308.60m |
| Revenue (TTM) | US$161.10m |
7.9x
P/S Ratio-4.1x
P/E RatioIs ARVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ARVN income statement (TTM) | |
|---|---|
| Revenue | US$161.10m |
| Cost of Revenue | US$0 |
| Gross Profit | US$161.10m |
| Other Expenses | US$469.70m |
| Earnings | -US$308.60m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.49 |
| Gross Margin | 100.00% |
| Net Profit Margin | -191.56% |
| Debt/Equity Ratio | 0.1% |
How did ARVN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 03:13 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Arvinas, Inc. is covered by 30 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Lawson | Barclays |
| null null | BMO Capital Markets Equity Research |
| Etzer Darout | BMO Capital Markets Equity Research |